精密生物科学宣布关键管理变革

• Precision BioSciences (DTIL) announced changes to its senior leadership team as the gene-editing company prepares to advance its lead clinical programs.
• Alex Kelly will be promoted from CFO to the newly created role of COO, where he will oversee key customer-facing functions, effective August 1.
• Naresh Tanna, currently VP of Investor Relations and Chief of Staff to the CEO, will succeed Kelly as CFO.

More on Precision BioSciences

• Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial Results Transcript
• Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial Results - Slideshow
• Precision BioSciences GAAP EPS of -$0.75 misses by $0.09, revenue of $10.84M beats by $6.79M
• Seeking Alpha’s Quant Rating on Precision BioSciences
• Historical earnings data for Precision BioSciences